Ionis Pharmaceuticals (IONS) Earnings Looks Straightforward as Ongoing Trials Will Present Future Catalysts - RBC Capital

February 25, 2021 7:07 AM EST
Get Alerts IONS Hot Sheet
Price: $42.36 -0.77%

Rating Summary:
    8 Buy, 9 Hold, 3 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 14 | New: 42
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

RBC Capital analyst Luca Issi reiterated an Outperform rating and $76.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) after the company hosted an uneventful earnings call. Guidance for 2021 (>$600m top line and $675-725m Opex) came generally in line with our model. Multiple readouts are on the horizon, including four Phase II in 1H21 (acromegaly, CF, HAE, hypertension) and five in 2H21 (pivotal SOD1-ALS, C9-ALS, Alzheimer, Huntington and dyslipidemia).

The analyst stated "We continue to like the setup given multiple ways to unlock value and somewhat limited downside given a strong revenue-generating base, optionality for future partnerships and a shareholder-friendly approach already self-sustainable." The analyst went on to state "Tegsedi/Waylivra commercial execution continues to be sluggish ($15-20m/quarter through 2020) but we believe Spinraza will be resilient given: 1) US decline is offset by ex US growth, 2) ongoing trials (RESPOND/DEVOTE) will incrementally improve the profile and 3) we are encouraged by management commentary today that some patients are moving back to Spinraza from Evrysdi."

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals click here. For more ratings news on Ionis Pharmaceuticals click here.

Shares of Ionis Pharmaceuticals closed at $56.21 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

RBC Capital, Earnings